Enovis (ENOV)
(Delayed Data from NYSE)
$43.00 USD
-0.44 (-1.01%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $43.00 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.00 USD
-0.44 (-1.01%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $43.00 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth C Momentum C VGM
Zacks News
Ensign (ENSG) Buys 2 Nursing Facilities in Tennessee & Nevada
by Zacks Equity Research
The acquisition deals have increased Ensign's (ENSG) portfolio to encompass 299 healthcare operations spanning 14 states.
Reasons to Retain HCA Healthcare (HCA) Stock in Your Portfolio
by Zacks Equity Research
HCA Healthcare's (HCA) improving top line, acquisition initiatives and a robust growth outlook poise the company well for growth.
Why You Should Retain Cigna (CI) Stock in Your Portfolio
by Zacks Equity Research
Cigna's (CI) strong Evernorth and Cigna Healthcare segments, growing medical membership and a positive 2023 outlook poise it well for growth.
Molina (MOH) to Pay Lower Price for California Medicare Buyout
by Zacks Equity Research
Molina Healthcare's (MOH) new price for Bright HealthCare's California Medicare business constitutes 23% of the anticipated $1.8 billion premium revenues for 2023.
Ensign Group (ENSG) Sanctions 4% Quarterly Dividend Hike
by Zacks Equity Research
Ensign Group (ENSG) announces a dividend hike, underlining a strong financial position and continued focus on deploying capital to shareholders.
Here's Why Investors Should Hold Elevance (ELV) Stock for Now
by Zacks Equity Research
Elevance's (ELV) Carelon unit will see growth due to improving performance in post-acute care services and Behavioral Health business.
Centene (CNC) Unveils its 2024 Projections: Key Takeaways
by Zacks Equity Research
Centene's (CNC) board boosts its share buyback program with a new $4 billion fund.
Cigna (CI) Adds $10B to Buyback Funds, Turns to Bolt-On Buyouts
by Zacks Equity Research
Cigna (CI) expects to maintain average annual adjusted EPS growth within 10-13% in the long term.
Evaluating Acadia Healthcare's (ACHC) Future View: Hold or Fold?
by Zacks Equity Research
Acadia Healthcare's (ACHC) top line is poised to capitalize on increasing patient days and bed capacity.
HCA Healthcare's (HCA) Houston Affiliate Acquires 11 EDs
by Zacks Equity Research
The deal helps HCA Healthcare (HCA) boost its freestanding EDs in the Houston region to 26, supplementing its existing hospital-based emergency rooms.
Humana (HUM) Extends CINQCARE's Home Care Model to MA Members
by Zacks Equity Research
Humana (HUM) teams up with CINQCARE to offer better health outcomes for its Medicare Advantage members of New York.
How Much Upside is Left in Enovis (ENOV)? Wall Street Analysts Think 38.3%
by Zacks Equity Research
The mean of analysts' price targets for Enovis (ENOV) points to a 38.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
UnitedHealth (UNH) Unveils its Latest Outlook: Key Takeaways
by Zacks Equity Research
UnitedHealth (UNH) expects the top line to be within the range of $400-$403 billion in 2024.
Here's Why Investors Should Hold Cigna (CI) Stock for Now
by Zacks Equity Research
Cigna (CI) expects total medical customer growth to be a minimum of 1.4 million this year.
Tenet (THC) to Divest 3 Hospitals to Novant to Reduce Debt
by Zacks Equity Research
Tenet (THC) expects the divestment of the three South Carolina hospitals to fetch around $2.4 billion in cash.
Encompass Health (EHC) Opens Second Hospital in Wisconsin
by Zacks Equity Research
The inpatient rehabilitation hospital's opening in Fitchburg, WI, was moved up from the initially scheduled first quarter of 2024.
HCA Healthcare (HCA) Unveils Ambitious 5-Year Growth Targets
by Zacks Equity Research
Over the five-year horizon, HCA Healthcare (HCA) anticipates substantial 8-12% annual growth in earnings per share.
Can Enovis (ENOV) Climb 43.82% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for Enovis (ENOV) points to a 43.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Brookdale Senior (BKD) Shares Rise 1.9% Despite Q3 Earnings Miss
by Zacks Equity Research
Brookdale Senior (BKD) expects adjusted EBITDA to be within the $77-$82 million range in the fourth quarter.
Enovis (ENOV) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Enovis (ENOV) delivered earnings and revenue surprises of 5.66% and 0.90%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Enovis (ENOV) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Enovis (ENOV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Enovis (ENOV) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Enovis (ENOV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Bear Of The Day: Enovis (ENOV)
by Brian Bolan
Despite a good history of beating the number, estimates are sliding for this Medical Information Systems provider
Enovis (ENOV) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Enovis (ENOV) delivered earnings and revenue surprises of 15.09% and 2.23%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Enovis (ENOV) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Enovis (ENOV) delivered earnings and revenue surprises of 18.92% and 4.12%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?